Market closed
Merck & Co./$MRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Ticker
$MRK
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
74,000
Website
Merck & Co. Metrics
BasicAdvanced
$199B
11.75
$6.74
0.36
$3.16
4.09%
Price and volume
Market cap
$199B
Beta
0.36
52-week high
$134.63
52-week low
$75.96
Average daily volume
18M
Dividend rate
$3.16
Financial strength
Current ratio
1.365
Quick ratio
0.873
Long term debt to equity
76.208
Total debt to equity
82.528
Dividend payout ratio (TTM)
45.80%
Interest coverage (TTM)
19.58%
Management effectiveness
Return on assets (TTM)
13.90%
Return on equity (TTM)
41.69%
Valuation
Price to earnings (TTM)
11.754
Price to revenue (TTM)
3.135
Price to book
4.51
Price to tangible book (TTM)
34.6
Price to free cash flow (TTM)
11.079
Dividend yield (TTM)
3.99%
Forward dividend yield
4.09%
Growth
Revenue change (TTM)
6.74%
Earnings per share change (TTM)
4,711.66%
3-year revenue growth (CAGR)
9.63%
3-year earnings per share growth (CAGR)
9.45%
3-year dividend per share growth (CAGR)
5.81%
What the Analysts think about Merck & Co.
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Merck & Co. Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Merck & Co. Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Merck & Co. News
AllArticlesVideos
Levi & Korsinsky Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK
Accesswire·8 hours ago
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky
Accesswire·11 hours ago
Trump Says Pharmaceutical Tariffs Coming in Near Future
Bloomberg Markets and Finance·11 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Merck & Co. stock?
Merck & Co. (MRK) has a market cap of $199B as of April 15, 2025.
What is the P/E ratio for Merck & Co. stock?
The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 11.75 as of April 15, 2025.
Does Merck & Co. stock pay dividends?
Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of April 15, 2025, the dividend rate is $3.16 and the yield is 4.09%. Merck & Co. has a payout ratio of 45.8% on a trailing twelve-month basis.
When is the next Merck & Co. dividend payment date?
The next Merck & Co. (MRK) dividend payment date is unconfirmed.
What is the beta indicator for Merck & Co.?
Merck & Co. (MRK) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.